Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033
Latest Information Update: 03 Nov 2026
At a glance
Most Recent Events
- 12 Oct 2026 According to a First Tracks Biotherapeutics media release, cohort 2 of the phase 1b celiac disease trial is evaluating mucosal healing over 12 weeks, with topline results anticipated in Q1 2027. A Phase 1b cohort evaluating ANB033 in eosinophilic esophagitis (EoE) is enrolling 50 patients, with topline data anticipated in Q3 2027
- 12 Oct 2026 Results presented in a First Tracks Biotherapeutics media release
- 12 Oct 2026 According to a First Tracks Biotherapeutics media release, company announced positive topline results from Cohort 1 (gluten challenge) of the Phase 1b clinical trial evaluating ANB033 in patients with celiac disease